N-Isopropenyl-N-methyl-acetamide | 14001-38-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Isopropenyl-N-methyl-acetamide
• 英文别名: N-methyl-N-prop-1-en-2-ylacetamide
• CAS: 14001-38-8
• 化学式: C₆H₁₁NO
• 分子量: 113.159
• InChiKey: BTOLKYABKKUYSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  α,α-Dimethyl-N-acetyl-sarkosinonitril 生成 N-Isopropenyl-N-methyl-acetamide
  参考文献：
  名称：

  Kurtz,P.; Disselnkoetter,H., Justus Liebigs Annalen der Chemie, 1972, vol. 764, p. 69 - 93

  摘要：

  DOI：

文献信息

• [EN] NOVEL COMPOUNDS AS ROR GAMMA MODULATORS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS EN TANT QUE MODULATEURS DE ROR GAMMA
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2017021879A1

  公开（公告）日：2017-02-09

  The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

  本公开涉及式(I)的化合物及其药用盐，其中环A、环B、L、R1、R2、R3、R4、R5、Ra、Rb、n、m、p和q如本文所定义，这些化合物作为视黄酸相关孤儿受体γt（RORγt）调节剂具有活性。这些化合物可以预防、抑制或抑制RORγt的作用，因此在治疗RORγt介导的疾病、紊乱、综合症或症状方面具有用处，例如疼痛、炎症、慢性阻塞性肺病（COPD）、哮喘、类风湿性关节炎、结肠炎、多发性硬化症、牛皮癣、神经退行性疾病和癌症。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3895707A1

  公开（公告）日：2021-10-20

  The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

  本发明提供了一种具有奥曲肽 2 型受体激动剂活性的杂环化合物。 由式（I）代表的化合物： 其中各符号如说明书所述，或其盐具有奥曲肽2型受体激动剂活性，可作为预防或治疗嗜睡症的药物。
• Methods for modulating the amount of RNA transcripts
  申请人：PTC Therapeutics, Inc.

  公开号：US10195202B2

  公开（公告）日：2019-02-05

  Described herein are methods for modulating the amount of a gene product and compounds for use in such methods. More particularly, described herein are methods for modulating the amount of an RNA transcript or protein product as the result of gene expression and compounds for use in such methods.

  本文描述的是调节基因产物量的方法和用于此类方法的化合物。更具体地说，这里描述的是调节作为基因表达结果的 RNA 转录物或蛋白质产物量的方法和用于这种方法的化合物。
• STABILISIERTE MONOMERENZUSAMMENSETZUNG
  申请人：BASF Aktiengesellschaft

  公开号：EP0885180B1

  公开（公告）日：2007-04-11
• INK COMPOSITION FOR 3D PRINTING SUPPORT AND 3D PRINTING MANUFACTURING METHOD USING THE SAME
  申请人：LG Chem, Ltd.

  公开号：US20180215937A1

  公开（公告）日：2018-08-02

  The present invention relates to an ink composition for a 3D printing support, comprising an amine-containing monomer and a curing agent. According to the present invention, an ink composition for a 3D printing support, which retains an excellent jetting property, is well dissolved in water after being photo-cured to be easily removed, and has less curing contraction and excellent storage stability, can be provided.